A randomized, double-blind, 24‐week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

References

• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). J Am Med Assoc 2003;289:3095–105
   PubMed Web of Science ®Google Scholar
• Üstün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386–92
   PubMed Web of Science ®Google Scholar
• Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. J Psychopharmacol 1994; 8:48–53
   Google Scholar
• Bauer M, Whybrow PC, Angst J, Versiani M, Möller H-J, WFSBP Task Force on Treatment. Guidelines for unipolar depressive disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 2002;3: 69–86
   Google Scholar
• Hochstrasser B, Isaksen PM, Koponen H, et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebocontrolled study of maintenance therapy. Br J Psychiatry 2001;178:304–10
   PubMed Web of Science ®Google Scholar
• Norman TR, Olver JS. New formulations of existing antidepressants: advantages in the management of depression. CNS Drugs 2004;18:505–20
   PubMed Web of Science ®Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331–6
   PubMed Web of Science ®Google Scholar
• Wade A, Lemming OM, Hedegaard KB. Escitalopram 10mg/ day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17: 95–102
   Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20mg/ day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18: 211–7
   Google Scholar
• Moore N, Verdoux H, Fantinoe B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131–7
   Google Scholar
• Bech P, Tanghøj P, Cialdella P, Andersen HF, Pedersen AG. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharm 2004;7:283–90
   PubMed Web of Science ®Google Scholar
• Colonna L, Reines EH, Andersen HF. Escitalopram is well tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. Int J Psychiatry Clin Prac 2002;6:243–4
   Google Scholar
• Auquier P, Robitail S, Llorca P-M, Rive B. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Prac 2003;7:259–68
   PubMed Web of Science ®Google Scholar
• Waugh J, Goa KL. Escitalopram. A review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003;17:343–62
   Google Scholar
• Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004;19:305–10
   PubMed Web of Science ®Google Scholar
• World Medical Association (WMA). Declaration of Helsinki: ethical principles for medical research involving human subjects, 1964
   Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994
   Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare. DHEW Publication No. (ADM) 218–222. Kensington, MD: The George Washington University; 1976
   Google Scholar
• Montgomery SA. Clinically relevant effect sizes in depression. Eur Neuropsychopharmacol 1994;4:283–4
   Google Scholar
• Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? Br Med J 2001;322:989–91
   PubMed Web of Science ®Google Scholar
• Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002;7(4 Suppl 1):40–4
   Google Scholar
• Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? – a pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004;19:149–55
   Google Scholar
• Kennedy SH, Eisfeld BS, Meyer JH, Bagby RM. Antidepressants in clinical practice: limitations of assessment methods and drug response. Hum Psychopharmacol 2001;16:105–14
   PubMed Web of Science ®Google Scholar